Qyuns Therapeutics-B (02509) 2025 Revenue Surges Over 4-Fold; Adjusted Profit Reaches Approximately RMB356 Million, Turning a Profit Year-on-Year [Yahoo! Finance]
ROCHE HOLDING LTD S/ADR (RHHBY)
NASDAQ:AMEX Investor Relations:
roche.com/investors.htm
Company Research
Source: Yahoo! Finance
Revenue amounted to approximately RMB807 million, representing a 4.08-fold year-on-year increase. Gross profit reached approximately RMB714 million, a 6.75-fold increase year-on-year. Profit for the year was RMB307 million, while adjusted profit for the year reached approximately RMB356 million, turning a profit compared with the same period last year. Earnings per share were RMB1.41. According to the announcement, the increase in revenue was mainly attributable to:(i) an increase of RMB622.5 million in licensing income, primarily relating to out-licensing transactions for QX030N and QX031N;(ii) an increase of RMB16.7 million in R&D service income, mainly driven by a RMB35.5 million growth in CDMO services, partially offset by a decrease in clinical service fees for QX004N and QX008N; and(iii) an increase of RMB9 million in the supply of Sailexin , consistent with the growth in sales of Sailexin . As of now, the Company has one commercialised product, namely Sailexin, the first us
Show less
Read more
Impact Snapshot
Event Time:
RHHBY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RHHBY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RHHBY alerts
High impacting ROCHE HOLDING LTD S/ADR news events
Weekly update
A roundup of the hottest topics
RHHBY
News
- Target RWE Strengthens Leadership Team with Appointments Across Delivery, Finance and Commercial [Yahoo! Finance]Yahoo! Finance
- Adrenocortical Carcinoma Market Report 2026: Innovative Therapies Set to Transform the $4 Billion Adrenocortical Carcinoma Landscape [Yahoo! Finance]Yahoo! Finance
- Abbisko Therapeutics' FGFR4 Inhibitor Irpagratinib Granted Orphan Drug Designation by EMA for Hepatocellular Carcinoma [TheStreet.com]TheStreet.com
- Abbott expands access to Precision Oncology portfolio through integration with Flatiron's OncoEMR® platform [Yahoo! Finance]Yahoo! Finance
- Roche receives FDA 510(k) clearance for cobas® c703 and cobas® ISE neo, next-generation analytical units enhancing efficiency and capability for laboratories [Yahoo! Finance]Yahoo! Finance